Clearmind Medicine Completes Enrollment for Second AUD Trial Cohort

Clearmind Medicine Inc. has successfully completed the enrollment of patients for the second cohort in its FDA-approved Phase I/IIa clinical trial assessing CMND-100, a proprietary oral drug candidate aimed at treating Alcohol Use Disorder (AUD). The announcement, made on December 16, 2025, reveals that six patients were enrolled rapidly across three leading clinical sites: Johns Hopkins University, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center.

This enrollment milestone follows the completion of the first cohort, which yielded promising top-line safety and efficacy data. The initial results reported a favorable safety profile and early indications of reduced cravings and withdrawal symptoms among participants. The swift enrollment of the second cohort underscores the commitment and operational efficiency of the collaborating clinical centers, highlighting their dedication to advancing innovative solutions for AUD, a condition that affects millions globally.

Dr. Adi Zuloff-Shani, Chief Executive Officer of Clearmind Medicine, expressed enthusiasm about the rapid progress. “We are thrilled with the accelerated pace of enrollment for our second cohort, which reflects the high level of interest from both patients and leading clinical sites in CMND-100’s potential to transform AUD treatment,” he stated. He emphasized that building on the encouraging results from the first cohort positions the company to gather additional valuable data, moving closer to delivering a breakthrough therapy designed to address the root causes of addiction with an improved safety profile.

Trial Design and Next Steps

The multinational Phase I/IIa trial is meticulously designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100 in individuals with moderate to severe AUD. Dosing for the second cohort is expected to begin shortly, with topline results anticipated within the coming months. Clearmind aims to leverage the insights gained from this trial to bring novel therapeutic options to the market, addressing a substantial unmet need in addiction treatment.

Clearmind Medicine is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics for various health problems, including AUD. The company’s goal is to research and develop these compounds for commercialization as regulated medicines, foods, or supplements. Currently, Clearmind holds an intellectual property portfolio comprising nineteen patent families, which include 31 granted patents. The company plans to pursue additional patents for its compounds as warranted and will remain open to acquiring further intellectual property to enhance its portfolio.

Shares of Clearmind are publicly traded on the Nasdaq under the symbol “CMND” and on the Frankfurt Stock Exchange under “CWY0.” For more information about the company and its ongoing initiatives, visit their website or contact their investor relations team.

This announcement includes forward-looking statements regarding the company’s expectations and potential developments. Such statements are based on current management beliefs and projections, which carry inherent uncertainties. Actual results may vary and are subject to various risks and challenges, as outlined in the company’s filings with the Securities and Exchange Commission.

Clearmind Medicine continues to prioritize transparency and aims to keep stakeholders informed as new developments arise in its clinical research efforts.